Axsome Therapeutics Inc (AXSM)

[BillyBahama]

and is on track to announce topline results in early January 2019, as previously disclosed. It's March 1st, no news yet.

Axsome has completed enrollment in the Phase 2 ASCEND study in major depressive disorder (MDD), and is on track to announce topline results in early January 2019, as previously disclosed. ASCEND is a multicenter, randomized, double-blind, controlled trial in which subjects with MDD are randomized to treatment with AXS-05 or bupropion.